PFG Investments LLC Purchases 503 Shares of Boston Scientific Corporation $BSX

PFG Investments LLC increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 6.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 8,403 shares of the medical equipment provider’s stock after acquiring an additional 503 shares during the quarter. PFG Investments LLC’s holdings in Boston Scientific were worth $903,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the first quarter worth about $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at approximately $27,000. Sound Income Strategies LLC increased its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the second quarter valued at approximately $37,000. Finally, Activest Wealth Management boosted its holdings in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 373 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $96.36 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a 50 day moving average price of $103.10 and a 200 day moving average price of $102.06. The stock has a market capitalization of $142.78 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares of the company’s stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Truist Financial raised their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a report on Wednesday. Canaccord Genuity Group lifted their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research report on Monday. Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Wednesday. Finally, Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.